# Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Canonical URL: https://biopharmsignal.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-september-investor-conferences-df55b00a
Ticker: STTK
Company: Shattuck Labs
Source: Shattuck Labs
Published: 2026-09-02 20:05 EST
## Summary

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage...

## Article Body
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

Conference Details

Wells Fargo 21 st Annual Healthcare Conference

Format: Fireside chat and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer Presentation Date: September 8, 2026 Time: 11:00 AM ET Webcast link: HERE

Cantor Global Healthcare Conference

Format: Fireside chat and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer Presentation Date: September 9, 2026 Time: 3:55 PM ET Webcast link: HERE

Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.shattucklabs.com . Replay webcasts will be available for approximately 30 days following the live presentations.

About Shattuck Labs, Inc. Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com .

Investor & Media Contact: Andrew R. Neill Chief Financial Officer Shattuck Labs, Inc. InvestorRelations@shattucklabs.com
## Recent Company News
- 2026-09-02 20:05 EST — [Shattuck Labs Announces Participation in Upcoming September Investor Conferences](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-september-investor-conferences-df55b00a) — Source: Shattuck Labs
- 2026-08-11 10:15 EST — [Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/STTK/shattuck-labs-reports-second-quarter-2026-financial-results-and-recent-business--3f3a5570) — Source: Shattuck Labs
- 2026-06-10 04:21 EST — [Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-pricing-of-75-million-public-offering-1147ed04) — Source: Shattuck Labs
- 2026-06-09 20:18 EST — [Shattuck Labs, Inc. Announces Proposed Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-proposed-public-offering-81c3c0e1) — Source: Shattuck Labs
- 2026-06-09 12:00 EST — [Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-exercise-of-outstanding-common-stock-warrants-and-provid-5897ec16) — Source: Shattuck Labs
## Related News
- 2026-09-09 23:25 EST — IRON — [Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-718b0075)
- 2026-09-09 20:17 EST — COO — [CooperCompanies Announces Third Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-third-quarter-2026-results-0256684b)
- 2026-09-09 20:15 EST — COO — [CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization](https://biopharmsignal.com/news/COO/coopercompanies-completes-strategic-review-increases-share-repurchase-authorizat-c3b7ff3b)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment](https://biopharmsignal.com/news/NBTX/nanobiotix-participera-la-conf-rence-h-c-wainwright-28th-annual-global-investmen-8b1208fb)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/NBTX/nanobiotix-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-co-bd8b771d)